Drug profile · INN
loncastuximab tesirine-lpyl
ZYNLONTA
loncastuximab tesirine-lpyl (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent. Associated with ADC Therapeutics SA. Route of administration: injection. Current US regulatory status: approved.
Drug details — loncastuximab tesirine-lpyl
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 1
- Programs
- 13
- Data quality
- 0.89
Quick answer
loncastuximab tesirine-lpyl (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent. Associated with ADC Therapeutics SA. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is loncastuximab tesirine-lpyl?
loncastuximab tesirine-lpyl (ZYNLONTA) is a b-lymphocyte antigen cd19 binding agent. Associated with ADC Therapeutics SA. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for loncastuximab tesirine-lpyl?
ZYNLONTA is a marketed brand name for loncastuximab tesirine-lpyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of loncastuximab tesirine-lpyl?
loncastuximab tesirine-lpyl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.